In combination with estrogen receptor inhibition, CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib) prolong survival in breast cancer and have led to a new therapeutic paradigm (Cristofanilli et al., 2016; Turner et al., 2018). Here, ESR1 is linked to breast carcinoma.